Topic: cardiovascular disease
A new $100 million (€85 million) capital fund out of Germany has closed and is looking for “ground-breaking” heart disease tech.
The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.
We tend to think of heart disease and heart disorders to be, in the main, things that affect men more than women, but this is not true.
Jazz Pharmaceuticals’ narcolepsy drug bested placebo at keeping patients awake during the day and tamping down on cataplexy attacks, or sudden paralysis.
Sanifit is breaking the mold in its native country: Back in June, it raised a massive €55.2 million ($62.9 million) series D round, smashing Spanish biotech VC records and ranking as one of the biggest life sciences raises in Europe for the year.
Launched in February with $250 million and a midphase heart disease drug from Novartis, Anthos’ sizable war chest means it can run large cardiovascular studies that are often beyond the reach of young biotech companies.
Philips is adding LindaCare’s remote monitoring platform for patients with cardiac implants to its IntelliSpace Cardiovascular informatics program.
Medicines Company is yet to share the efficacy data that will show whether inclisiran can compete but has sought to tackle lingering safety concerns.
Reinhardt, who helped GlaxoSmithKline get a gene therapy to market, joins XyloCor to advance genetic treatments for cardiovascular diseases.
Bayer tapped Sensyne Health to sift through patient data from the NHS and apply the findings to its cardiovascular disease pipeline.